UK Authorizes Once-Every-Four-Weeks IV Maintenance Dosing of Leqembi for Early Alzheimer’s

The decision offers a less frequent infusion option for eligible early‑stage patients following the initial 18‑month schedule.

Overview

After 18 months at 10 mg/kg every two weeks, patients may switch to 10 mg/kg every four weeks for IV maintenance or remain on the biweekly regimen.
In the UK, Leqembi was previously cleared for adults with mild cognitive impairment or mild dementia due to Alzheimer’s who are ApoE ε4 heterozygotes or non‑carriers.
The label expansion rests on Phase 3 Clarity AD results, where lecanemab met its primary endpoint and all key secondary endpoints with statistical significance.
IV maintenance dosing following the initial phase is now approved in the UK, the United States, China, and other markets, reflecting broader global uptake.
In the United States, Leqembi Iqlik is authorized for subcutaneous maintenance with an autoinjector, and a rolling FDA submission for subcutaneous initiation dosing began in September 2025.